This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Toung, T. K. Articles by Faraci, F. M. Search for Related Content PubMed PubMed Citation Articles by Toung, T. K. Articles by Faraci, F. M. Related Collections Animal models of human disease Acute Cerebral Infarction Risk Factors for Stroke

(Stroke. 2000;31:2701.)
© 2000 American Heart Association, Inc.

Original Contribution

Estrogen Decreases Infarct Size After Temporary Focal Ischemia in a Genetic Model of Type 1 Diabetes Mellitus

Thomas K. Toung, MD; Patricia D. Hurn, PhD; Richard J. Traystman, PhD Frederick E. Sieber, MD

From the Department of Anesthesiology and Critical Care Medicine, Johns Hopkins Medical Institutions, and the Department of Anesthesiology (F.E.S.), Johns Hopkins Bayview Medical Center, Baltimore, Md.

Correspondence to Frederick E. Sieber, MD, Vice Chairman, Department of Anesthesiology, Johns Hopkins Bayview Medical Center, 4940 Eastern Ave, Baltimore, MD 21224-2780. E-mail fsieber{at}jhmi.edu

Background and Purpose—It is unclear how genetic type 1 diabetes mellitus (DM) influences infarct size when blood glucose is tightly controlled. The aim of this study was to determine the effect of genetic type 1 DM, as occurs in BB rats, on infarct size after transient unilateral middle cerebral artery occlusion (MCAO) in male and female rats. In addition, studies suggest that male type 1 DM rats have a higher incidence of end-organ complications than do females. A second aim of this study was to determine the effect of chronic 17ß-estradiol (E₂) administration on infarct size in male BB rats.

Methods—Diabetic male (MDiab, n=14) and female (FDiab, n=8) BB rats were studied and compared with background strain Wistar rats (MWist, n=16; FWist, n=14). Two additional male cohorts (MWist+E₂, n=15; MDiab+E₂, n=14) received subcutaneous 25 µg E₂ implants 7 to 10 days before MCAO. Rats underwent 1 hour of MCAO followed by 22 hours of reperfusion. Physiological variables were controlled among groups, and the intraischemic laser Doppler flow signal was reduced similarly in all animals. Infarction volume was evaluated by 2,3,5-triphenyltetrazolium chloride staining and image analysis.

Results—Preischemic blood glucose was 94±5, 127±13, 90±15, 63±18, 122±8, and 81±14 mg/dL in MWist, FWist, MDiab, FDiab, MWist+E₂, and MDiab+E₂ rats, respectively (mean±SE). Intraischemic laser Doppler flow was reduced to 20% to 25% of baseline in all groups. Striatal infarct size (percentage of ipsilateral caudate putamen) was increased in male diabetic rats relative to nondiabetic MWist rats (41±3% versus 28±3%). Striatal injury was not increased in FDiab rats, and infarction volume was smaller than that in FWist rats (23±4% in FWist versus 13±3% in FDiab). Chronic estrogen treatment reduced cortical and striatal infarction in MDiab+E₂ rats compared with untreated MDiab rats.

Conclusions—Type 1 DM is associated with increased infarct size after temporary MCAO, despite tight control of blood glucose. The deleterious effect of DM is evident only in males rats; female diabetic BB rats sustain small infarcts. Chronic E₂ treatment reduced injury in the male BB rat, providing neuroprotection even in the presence of DM. These data suggest that genetic diabetes even with mild glucose elevation plays a role in determining neuropathology in experimental stroke. However, factors such as reproductive steroids also determine outcome in DM stroke.

Editorial Comment

Frank M. Faraci, PhD, Guest Editor

Department of Internal Medicine Cardiovascular Division University of Iowa College of Medicine Iowa City, Iowa

This article has been cited by other articles:

				J. W. Simpkins, E. Perez, Xiaofei Wang, ShaoHua Yang, Yi Wen, and M. Singh Review: The potential for estrogens in preventing Alzheimer's disease and vascular dementia Therapeutic Advances in Neurological Disorders, January 1, 2009; 2(1): 31 - 49. [Abstract] [PDF]

				M. Singh, J. A. Dykens, and J. W. Simpkins Novel Mechanisms for Estrogen-Induced Neuroprotection. Experimental Biology and Medicine, May 1, 2006; 231(5): 514 - 521. [Abstract] [Full Text] [PDF]

				P. D. Hurn, S. J. Vannucci, and H. Hagberg Adult or Perinatal Brain Injury: Does Sex Matter? Stroke, February 1, 2005; 36(2): 193 - 195. [Full Text] [PDF]

				J. W. Simpkins, S.-H. Yang, R. Liu, E. Perez, Z. Y. Cai, D. F. Covey, and P. S. Green Estrogen-Like Compounds for Ischemic Neuroprotection Stroke, November 1, 2004; 35(11_suppl_1): 2648 - 2651. [Abstract] [Full Text] [PDF]

				L. B. Becker, M. L. Weisfeldt, M. H. Weil, T. Budinger, J. Carrico, K. Kern, G. Nichol, I. Shechter, R. Traystman, C. Webb, et al. The PULSE Initiative: Scientific Priorities and Strategic Planning for Resuscitation Research and Life Saving Therapies Circulation, May 28, 2002; 105(21): 2562 - 2570. [Full Text] [PDF]